EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma

Zeyu Li iD, Shaoqiang Xing, Sheng Zeng iD, Yifei Zhang, Yaowen Li iD, Qian Liu iD

Genetics Research · 2026-01 · 2026 (1)

DOI: 10.1155/genr/4050985 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetics Research, online erschienen am 09.11.2026. Verfasst von Zeyu Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tianjin First Central Hospital, Tianjin, 300071, China, tj-fch.com. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Sunitinib, Kidney Neoplasms, Immunotherapy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Health Science and Technology Project, Tianjin Key Medical Discipline (Specialty) Construction Project, Natural Science Foundation of Tianjin City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to immune checkpoint inhibitors and VEGFR‐targeted agents limits durable disease control in clear cell renal cell carcinoma (ccRCC). We examined a tumour cell proliferative transcriptional programme in relation to treatment response and progression‐free survival (PFS).

Methods

We analysed predominantly unpaired baseline and progression single‐cell transcriptomes from anti‐PD‐1‐treated ccRCC. A fixed 20‐gene signature underwent patient‐adjusted pseudobulk and RNA‐inferred copy‐number analyses. Pretreatment scores were evaluated in 332 patients across four immunotherapy or sunitinib groups from three studies, with established proliferation benchmarks and time‐varying survival analyses.

Results

The discovery comparison included five baseline and six progression patients. All 20 genes, including PLK1, UBE2C and CDC20, retained higher expression in the proliferative cluster after patient adjustment, although its abundance difference did not survive multiple‐testing correction (BH‐adjusted q = 0.164). The score closely tracked G2M ( r = 0.915–0.980), without superior PFS discrimination in the primary benchmark. Inclusive response AUCs were 0.519 for IMmotion150 immunotherapy, 0.569 for IMmotion150 sunitinib and 0.693 for E‐MTAB‐3267. In E‐MTAB‐3267, the age‐ and sex‐adjusted HR was 1.54 per score standard deviation (95% CI 1.13–2.11). The IMmotion150 immunotherapy association weakened over follow‐up; excluding this nonproportional estimate yielded a pooled HR of 1.51 (95% CI 1.24–1.83) in 158 patients.

Conclusion

Single‐cell and bulk transcriptomic analyses connect a proliferative gene‐expression programme with adverse PFS during immunotherapy and sunitinib treatment in ccRCC. The signature provides a compact transcriptional readout of proliferation associated with treatment outcomes, with a stronger relationship to PFS than to objective response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellSunitinibKidney NeoplasmsImmunotherapyHumansProgression-Free SurvivalCell ProliferationFemaleSingle-Cell AnalysisTranscriptomeMaleGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

VEGFR-targeted therapyclear cell renal cell carcinomaimmune checkpoint inhibitionproliferationsingle-cell RNA sequencingtranscriptomic signature

Substanzen

Sunitinib

Autor:innen und Institutionen

  • Department of Urology, Tianjin First Central Hospital, Tianjin, 300071, China, tj-fch.com.
  • The First Central Clinical School, Tianjin Medical University, Tianjin, 300071, China, tijmu.edu.cn.
  • Department of Urology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, 453100, China, xxmu.edu.cn.
  • Tianjin First Central Hospital, Nankai University, Tianjin, 300071, China, nankai.edu.cn.

ORCID-Profile: Zeyu Li, Sheng Zeng, Yaowen Li, Qian Liu

Förderung

  • Tianjin Health Science and Technology Project
  • Tianjin Key Medical Discipline (Specialty) Construction Project
  • Natural Science Foundation of Tianjin City
  • National Natural Science Foundation of China

Zitieren

APA

Li, Z., Xing, S., Zeng, S., Zhang, Y., Li, Y., & Liu, Q. (2026). A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma. Genetics Research, 2026(1). https://doi.org/10.1155/genr/4050985

Vancouver

Li Z, Xing S, Zeng S, Zhang Y, Li Y, Liu Q. A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma. Genetics Research. 2026;2026(1). doi:10.1155/genr/4050985

BibTeX
@article{Li2026,
  author = {Li, Zeyu and Xing, Shaoqiang and Zeng, Sheng and Zhang, Yifei and Li, Yaowen and Liu, Qian},
  title = {A Single‐Cell‐Derived Proliferative Signature Is Associated With Progression‐Free Survival During Immunotherapy and Sunitinib Treatment in Clear Cell Renal Cell Carcinoma},
  journal = {Genetics Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/genr/4050985}
}
Kostenlos starten →